Rocket Pharmaceuticals, Inc. Other Income and Expense
Rocket Pharmaceuticals, Inc. (RCKT) reported Other Income and Expense of $2.48 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2023-02-28
- Rocket Pharmaceuticals, Inc. nonoperating income (expense) for fiscal 2022 was $2.48M.
- Rocket Pharmaceuticals, Inc. nonoperating income (expense) for fiscal 2021 was -$1.82M.
- Rocket Pharmaceuticals, Inc. nonoperating income (expense) for fiscal 2020 was -$5.40M.
| Period end | Nonoperating Income (Expense) 12 month |
|---|---|
| 2022-12-31 | $2.48M 10-K · filed 2023-02-28 |
| 2021-12-31 | -$1.82M 10-K · filed 2023-02-28 |
| 2020-12-31 | -$5.40M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |